Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Frankfurt am Main Germany (1908)

Organization Overview

First Clinical Trial
2005
NCT00405886
First Marketed Drug
1985
erythromycin (ilosone)
First NDA Approval
2010
incobotulinumtoxinA (Xeomin)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LLC Merz Pharma, Russia | Merz Aesthetics | Merz Aesthetics Inc. | Merz North America | Merz North America, Inc. | Merz Pharmaceutical, LLC | Merz Pharmaceuticals | Merz Pharmaceuticals GmbH | Merz Pharmaceuticals, LLC | MERZ PHARMS